D. Valteau Couanet

Image‐defined risk factors in unresectable neuroblastoma: SIOPEN study on incidence, chemotherapy‐induced variation, and impact on surgical outcomes

Giovanni Cecchetto, Giovanni Erminio, Victoria Castel, 2017, Pediatric blood & cancer.

Busulphan-melphalan as a myeloablative therapy (MAT) for high-risk neuroblastoma: Results from the HR-NBL1/SIOPEN trial.

M. Garami, I. Yaniv, T. Trahair, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Busulphan-melphalan as a myeloablative therapy (MAT) for high-risk neuroblastoma: Results from the HR-NBL1/SIOPEN trial.

M. Garami, I. Yaniv, T. Trahair, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.